|
gptkbp:instanceOf
|
inhalational anesthetic
volatile anesthetic
|
|
gptkbp:approvedBy
|
gptkb:FDA
1995
|
|
gptkbp:aroma
|
mild, pleasant
|
|
gptkbp:ATCCode
|
N01AB08
|
|
gptkbp:boilingPoint
|
58.5°C
|
|
gptkbp:brand
|
gptkb:Sevorane
gptkb:Ultane
|
|
gptkbp:CASNumber
|
28523-86-6
|
|
gptkbp:category
|
Ether
organofluorides
general anesthetic
|
|
gptkbp:chemicalFormula
|
C4H3F7O
|
|
gptkbp:color
|
colorless
|
|
gptkbp:contraindication
|
history of malignant hyperthermia
hypersensitivity to sevoflurane
|
|
gptkbp:discoveredBy
|
gptkb:Ross_Terrell
1971
|
|
gptkbp:eliminationHalfLife
|
15-23 minutes
|
|
gptkbp:excretion
|
lungs
|
|
gptkbp:firstSynthesized
|
gptkb:Ross_Terrell
|
|
gptkbp:flammability
|
non-flammable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sevoflurane
|
|
gptkbp:IUPACName
|
gptkb:fluoromethyl_2,2,2-trifluoro-1-(trifluoromethyl)ethyl_ether
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits NMDA receptor activity
potentiates GABA-A receptor activity
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:minimum_alveolar_concentration_(MAC)
|
2.0% (adults)
|
|
gptkbp:molecularWeight
|
200.05 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
hepatotoxicity (rare)
nephrotoxicity (rare)
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
nausea
malignant hyperthermia
hypotension
respiratory depression
|
|
gptkbp:solubility_in_blood
|
low
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
QGA86A1P3F
|
|
gptkbp:used_in
|
outpatient surgery
induction of anesthesia
maintenance of anesthesia
veterinary anesthesia
pediatric anesthesia
|
|
gptkbp:usedFor
|
general anesthesia
|
|
gptkbp:vapor_pressure_at_20°C
|
157 mmHg
|
|
gptkbp:bfsParent
|
gptkb:Purdue_Pharma
|
|
gptkbp:bfsLayer
|
6
|